Cellectis Logo
FR0010425595
A0MKPR
ALCLS.PA

Cellectis

Caricamento quotazioni...

Previsioni

Acquista
  13
Mantieni
  2
Vendi
  1

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Cellectis reports quarterly loss per share of $0.26 and declining revenue

    Cellectis reported earnings per share of -$0.26 for the most recent quarter, after -$0.080 in the year-ago quarter. Quarterly revenue fell to $10.4 million (-17.74% versus $12.6 million). For the full year, the company shows a loss per share of -$0.670, while annual revenue rose sharply to $73.17 million (±76.61% versus $41.43 million). » Altro su finanzen.net


  • Cellectis beats Q4 2025 revenue and EPS forecasts, stock rises

    Cellectis reported Q4 2025 EPS of -$0.19 (forecast -$0.2948) and revenue of $17.1 million (forecast $10.02 million), both well above expectations. The stock rose 2.01% in premarket trading to $3.55. Cash resources of $211 million secure the company’s financial runway into the second half of 2027. The company highlights progress on the Lasme‑Cel and Eti‑Cel programmes and the validation of internal manufacturing capacities. » Altro su de.investing.com


  • Cellectis: arbitration panel partially terminates license agreement with Servier

    An arbitration panel has partially terminated the 2019 license, development and commercialization agreement between Cellectis and Servier. The decision specifically concerns the product UCART19 V1 (also ALLO-501) and obliges Cellectis, upon request, to enter into good-faith negotiations with Allogene regarding a direct licensing arrangement. All other claims brought in the arbitration were dismissed. » Altro su de.investing.com


  • Cellectis achieves breakthrough in non-viral gene insertion method

    Cellectis and Moligo present in Nature Communications a non-viral gene insertion method for hematopoietic stem and progenitor cells (HSPCs) based on enzymatically produced circular single-stranded DNA (CssDNA). The circular ssDNA format reached insertion rates above 40% and was 3- to 5-fold more efficient than linear ssDNA; in mouse models, CssDNA-edited HSPCs showed better expansion and retention of edits than with AAV6. The collaboration aims to provide a scalable alternative to viral vectors and strengthen Cellectis' position in gene editing, while analysts see a price target of $7.50 and the company, despite strong revenue growth, is not yet profitable. » Altro su de.investing.com


  • Cellectis reports strong phase‑1 data for leukemia therapy lasme‑cel

    Cellectis released promising phase‑1 data from the BALLI‑01 study of lasme‑cel (UCART22) in relapsed/refractory B‑ALL: overall response rate 68% (manufacturing process 2), 83% at the dose recommended for phase‑2 and 100% in the phase‑2 target population. In that target group, 56% achieved complete remission (CR/CRi) and about 80% were minimal residual disease (MRD) negative; 78% of patients eligible for transplant received one. The therapy showed activity even in heavily pretreated patients and was generally well tolerated. Cellectis has initiated a registration‑enabling phase‑2 study (first patient expected Q4 2025) and is targeting a BLA submission in 2028; Q2 financials showed mixed signals with revenue above forecast but an EPS miss. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Cellectis ha registrato ricavi pari a 3,76 Mln € e un utile netto di -61,47 Mln €
(EUR) settembre 2026
YoY
Ricavi 3,76 Mln 89,30%
Utile lordo 1,27 Mln 96,13%
Utile netto -61,47 Mln 10.537,01%
EBITDA -27,79 Mln 460,63%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
71,53 Mln €
Numero di azioni
72,33 Mln
Massimo/minimo a 52 settimane
4,75 € - 0,90 €
Dividendi No
Beta
2,91
Rapporto P/E
-0,85
Rapporto PEG
0,01
Rapporto P/B
-6,20
Rapporto P/S
3,12

Profilo aziendale

Cellectis S.A., una società biotecnologica in fase clinica, sviluppa prodotti di immuno-oncologia basati su linfociti T geneticamente modificati che esprimono recettori antigenici chimerici per colpire e distruggere le cellule tumorali. L'azienda opera attraverso due segmenti, Therapeutics e Plants. La società sta sviluppando UCART19, un candidato prodotto a base di linfociti T allogenici per il trattamento di neoplasie ematologiche che esprimono CD19, come la leucemia linfoblastica acuta; ALLO-501 e ALLO-501A per il trattamento del linfoma diffuso a grandi cellule B recidivante/refrattario e del linfoma follicolare; ALLO-316 per il trattamento del carcinoma a cellule renali; UCART123 per il trattamento della leucemia mieloide acuta; e UCART22 per il trattamento della leucemia linfoblastica acuta a cellule B. Sta inoltre sviluppando UCARTCS1 e ALLO-715 per il trattamento del mieloma multiplo. La società ha alleanze strategiche con Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; e Iovance Biotherapeutics, nonché una collaborazione strategica di ricerca e sviluppo con Cytovia Therapeutics, Inc. Cellectis S.A. è stata fondata nel 1999 ed ha sede a Parigi, in Francia.

Nome
Cellectis
CEO
Andre Choulika
Sede centrale Paris, if
Francia
Sito web
Quotazione in borsa
07/02/2007
Dipendenti 227

Simboli di borsa

Borsa Simbolo
Euronext
ALCLS.PA
Pnk
CMVLF
Frankfurt
ZVA.F
Düsseldorf
ZVA.DU
London
0WA2.L
Paris
ALCLS.PA
München
ZVA.MU
🍪

Parqet  usa i cookie. Scopri di più